title: Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.
abstract: Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8(+) T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.
authors.affiliation: Department of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands Department of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
authors.forename: N
authors.initials: N
authors.lastname: Oreshkova
authors.affiliation: Department of Pediatric Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.
authors.forename: L
authors.initials: L
authors.lastname: Spel
authors.affiliation: Department of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands.
authors.forename: R P M
authors.initials: RP
authors.lastname: Vloet
authors.affiliation: Department of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands.
authors.forename: P J
authors.initials: PJ
authors.lastname: Wichgers Schreur
authors.affiliation: Department of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands Department of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
authors.forename: R J M
authors.initials: RJ
authors.lastname: Moormann
authors.affiliation: Department of Pediatric Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Boes
authors.affiliation: Department of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands jeroen.kortekaas@wur.nl.
authors.forename: J
authors.initials: J
authors.lastname: Kortekaas
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology* / Q000821:virology; D000939:Epitopes / Q000235:genetics / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation / Q000276:immunology; D008223:Lymphoma / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D010750:Phosphoproteins / Q000235:genetics / Q000276:immunology; D012296:Rift Valley fever virus / Q000235:genetics / Q000276:immunology*; D014611:Vaccination; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D000939:Epitopes; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa